Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in March:
- Raymond James 42nd Annual Institutional Investors Conference: Fireside chat on Monday, March 1, 2021 at 9:10 a.m. ET.
- Cowen 41st Annual Health Care Conference: New Drug Launches panel on Wednesday, March 3, 2021 at 10:20 a.m. ET.
- Oppenheimer 31st Annual Healthcare Conference: Fireside chat on Wednesday, March 17, 2021 at 8:40 a.m. ET.
The Raymond James and Oppenheimer Conference events will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at . Replays of the webcasts will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit .
Investor Contact:
Argot Partners
212.600.1902
